Header Logo

Connection

MILIND JAVLE to Mutation

Back to Details
This is a "connection" page, showing publications MILIND JAVLE has written about Mutation.
MILIND JAVLE
Connection Strength
0.979
Mutation
  1. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
    View in: PubMed
    Score: 0.126
  2. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014 Apr; 45(4):701-8.
    View in: PubMed
    Score: 0.116
  3. Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 Mar; 8:e2300544.
    View in: PubMed
    Score: 0.059
  4. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Curr Oncol Rep. 2021 07 16; 23(9):108.
    View in: PubMed
    Score: 0.049
  5. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 12 16; 10(1):22087.
    View in: PubMed
    Score: 0.048
  6. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
    View in: PubMed
    Score: 0.046
  7. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
    View in: PubMed
    Score: 0.044
  8. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019 01; 156(1):108-118.e4.
    View in: PubMed
    Score: 0.041
  9. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282.
    View in: PubMed
    Score: 0.038
  10. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. J Natl Compr Canc Netw. 2017 08; 15(8):1063-1069.
    View in: PubMed
    Score: 0.038
  11. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 07; 22(7):804-810.
    View in: PubMed
    Score: 0.037
  12. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol. 2016 11; 17(11):58.
    View in: PubMed
    Score: 0.036
  13. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122(24):3838-3847.
    View in: PubMed
    Score: 0.035
  14. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 12 01; 122(23):3657-3666.
    View in: PubMed
    Score: 0.035
  15. Mutational Profiles Reveal an Aberrant TGF-?-CEA Regulated Pathway in Colon Adenomas. PLoS One. 2016; 11(4):e0153933.
    View in: PubMed
    Score: 0.034
  16. Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Additional Options for an Orphan Cancer. J Mol Diagn. 2016 05; 18(3):388-394.
    View in: PubMed
    Score: 0.034
  17. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer. 2024 03 26; 23(1):64.
    View in: PubMed
    Score: 0.015
  18. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res. 2023 12 01; 29(23):4853-4862.
    View in: PubMed
    Score: 0.015
  19. Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334.
    View in: PubMed
    Score: 0.015
  20. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist. 2023 04 06; 28(4):327-332.
    View in: PubMed
    Score: 0.014
  21. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol. 2022 Dec; 33(12):1269-1283.
    View in: PubMed
    Score: 0.013
  22. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677.
    View in: PubMed
    Score: 0.013
  23. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 09; 21(9):1234-1243.
    View in: PubMed
    Score: 0.012
  24. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Oct; 16(30):2375-2384.
    View in: PubMed
    Score: 0.011
  25. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.010
  26. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
    View in: PubMed
    Score: 0.010
  27. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018 05; 3(5):337-348.
    View in: PubMed
    Score: 0.010
  28. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
    View in: PubMed
    Score: 0.009
  29. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol. 2016 May; 69(5):403-8.
    View in: PubMed
    Score: 0.008
  30. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat Med. 2014 Jun; 20(6):596-8.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.